Current developments for the diagnosis and treatment of irritable bowel syndrome

Oliver Grundmann, Saunjoo L. Yoon, Baharak Moshiree

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.

Original languageEnglish
Pages (from-to)3638-3645
Number of pages8
JournalCurrent Pharmaceutical Design
Volume16
Issue number33
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Chlorides
Tryptophan Hydroxylase
Corticotropin-Releasing Hormone Receptors
Therapeutics
Cholecystokinin
Probiotics
Pharmaceutical Preparations
Monoclonal Antibodies
Clinical Trials
Pharmacology
Drug Therapy
Enzymes

Keywords

  • 5-ht
  • Clinical trials
  • Drug development
  • Inflammation
  • Irritable bowel syndrome

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Current developments for the diagnosis and treatment of irritable bowel syndrome. / Grundmann, Oliver; Yoon, Saunjoo L.; Moshiree, Baharak.

In: Current Pharmaceutical Design, Vol. 16, No. 33, 01.11.2010, p. 3638-3645.

Research output: Contribution to journalArticle

Grundmann, Oliver ; Yoon, Saunjoo L. ; Moshiree, Baharak. / Current developments for the diagnosis and treatment of irritable bowel syndrome. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 33. pp. 3638-3645.
@article{66f12a5320ae436a8b73945c31ac7ef3,
title = "Current developments for the diagnosis and treatment of irritable bowel syndrome",
abstract = "Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.",
keywords = "5-ht, Clinical trials, Drug development, Inflammation, Irritable bowel syndrome",
author = "Oliver Grundmann and Yoon, {Saunjoo L.} and Baharak Moshiree",
year = "2010",
month = "11",
day = "1",
doi = "10.2174/138161210794079227",
language = "English",
volume = "16",
pages = "3638--3645",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "33",

}

TY - JOUR

T1 - Current developments for the diagnosis and treatment of irritable bowel syndrome

AU - Grundmann, Oliver

AU - Yoon, Saunjoo L.

AU - Moshiree, Baharak

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.

AB - Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.

KW - 5-ht

KW - Clinical trials

KW - Drug development

KW - Inflammation

KW - Irritable bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=79955686853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955686853&partnerID=8YFLogxK

U2 - 10.2174/138161210794079227

DO - 10.2174/138161210794079227

M3 - Article

VL - 16

SP - 3638

EP - 3645

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 33

ER -